Evaluating the advantages and potential drawbacks of shielding as a method for safe RL. Bettina Könighofer is an assistant professor at Graz University of Technology, Graz, Austria. Roderick Bloem ...

NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the "Company"), announced that its clinical lead drug NV ...

Results from pritelivir Phase 2 study demonstrate a favorable safety profile and a numerically higher lesion healing rate vs. foscarnetPritelivir Phase 2 results supported FDA Breakthrough Therapy ...

A genetically engineered herpes virus may offer a new and effective treatment for advanced melanoma, providing hope for ...

The FDA accepted a new drug application for a single inhaler that contains beclomethasone dipropionate, formoterol fumarate ...

Pritelivir demonstrated clinically meaningful and highly statistically significant superiority (p=0.0047) in lesion healing up to 28 days of ...

Aicuris has reported the success of a phase 3 trial, which has demonstrated the superiority of oral antiviral pritelivir ...

NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), reports that an analyst research report was published on the ...

Moderna faces significant uncertainty ahead of Q3 earnings, with heavy reliance on COVID vaccine revenues and limited ...

Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, ...

Late-breaking oral presentation highlights interim Phase 1b data reported earlier this year for two cohorts in participants with recurrent ...

Assembly Biosciences (ASMB) announced that interim Phase 1b clinical data for its long-acting herpes simplex virus helicase-primase inhibitor ...